BioToxTech Co

BioToxTech Co Financial Debt Ratio

The Financial Debt Ratio of BioToxTech Co (086040.KQ) as of Nov 22, 2026 is 8.55 %. In the previous year, Financial Debt Ratio was 28.28 % — a change of -69.77% (lower).

Financial Debt Ratio

8.55 %

YoY

-69.77%

Last updated:

Financial Debt Ratio of BioToxTech Co is 2025 8.55 % . Financial Debt Ratio of BioToxTech Co was 2024 28.28 % . It decreases by -69.77% lower compared to the previous year.

The BioToxTech Co Financial Debt Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Debt Ratio
Date
Financial Debt Ratio
Jan 1, 2018
26.55 KRW
Jan 1, 2019
27.61 KRW
Jan 1, 2020
19.37 KRW
Jan 1, 2021
16.92 KRW
Jan 1, 2022
27.44 KRW
Jan 1, 2023
29.94 KRW
Jan 1, 2024
28.28 KRW
Jan 1, 2025
8.55 KRW
The BioToxTech Co Financial Debt Ratio history
YEARFinancial Debt RatioYoY
8.55 %-69.77%
28.28 %-5.56%
29.94 %+9.13%
27.44 %+62.19%
16.92 %-12.69%
19.37 %-29.83%
27.61 %+3.98%
26.55 %+3.75%
25.59 %-8.92%
28.10 %-9.63%
31.09 %+494.88%
5.23 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioToxTech Co Stock analysis

What does BioToxTech Co do? Biotoxtech Co., Ltd. generates revenue through non-clinical drug trials, offering safety evaluation research, efficacy evaluation research, and analysis research services. Safety evaluation includes general toxicity, local toxicity, reproductive and development, genotoxicity, immunotoxicity, carcinogenicity, safety pharmacology, ecotoxicology, histopathology, and hematology tests. Efficacy evaluation covers medical supplies, health supplements, and cosmetics. Analysis research provides pharmacokinetics (PK) and toxicokinetics (TK) tests, validation, and bio analysis services. The company serves clients requiring preclinical testing for pharmaceuticals, health products, and cosmetics. The firm expanded its operations by acquiring a 60% stake in a newly established subsidiary on March 13, 2013. This strategic move enhances its capacity to deliver comprehensive research services. Clients include pharmaceutical companies, health supplement manufacturers, and cosmetic brands seeking regulatory compliance and product safety validation before market entry. Biotoxtech's service portfolio targets the pharmaceutical, health supplement, and cosmetic industries. Its safety and efficacy testing ensures products meet regulatory standards, supporting clients in developing safe and effective formulations. The company's analysis research further aids in optimizing drug delivery and performance through PK and TK assessments. BioToxTech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioToxTech Co stock

Financial Debt Ratio of BioToxTech Co is 8.55 % in 2025.

Financial Debt Ratio of BioToxTech Co changed from 28.28 % to 8.55 %, representing a -69.77% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Debt Ratio BioToxTech Co since 2006 – with annual values, charts, and detailed analysis.

The financial debt ratio measures interest-bearing financial debt as a percentage of total assets. It isolates funded debt from trade and other non-financial obligations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Debt Ratio's BioToxTech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — BioToxTech Co

All Key Metrics — BioToxTech Co